CURRENT
ISSUE
1768

Two new blood tests for biomarkers that correlate with brain amyloid beta pathology have been cleared by the FDA to aid in the diagnosis of Alzheimer's disease (AD): Elecsys Phospho-Tau (217P) Plasma assay (Roche) and PrecivityAD2 (C2N Diagnostics). Other FDA-cleared blood tests for AD biomarkers are listed in Table 1.1,2 The amyloid beta-directed antibodies lecanemab (Leqembi, and others) and donanemab (Kisunla) are available for treatment of AD in patients with mild cognitive impairment or mild dementia who have confirmed brain amyloid pathology. Continue reading

Coming Soon
Drugs for Parkinson's Disease
Tebipenem Pivoxil (Utebzi) – An Oral Carbapenem for Complicated UTI
Asundexian (Sunharbo) for Stroke Prevention
Milsaperidone (Bysanti) for Schizophrenia and Bipolar Disorder